Back to Search
Start Over
Neutralising antibodies to interferon during the treatment of multiple sclerosis
- Source :
- Journal of Neurology, Neurosurgery & Psychiatry. 74:1162-1162
- Publication Year :
- 2003
- Publisher :
- BMJ, 2003.
-
Abstract
- Giovannoni and colleagues are to be commended for their detailed analysis of the impact of neutralising antibodies (NAB) to interferon β (IFNβ) during the treatment of multiple sclerosis.1 We are in general agreement with many of their statements and conclusions, but a few points should be discussed in a wider context. With respect to the clinical significance of neutralising antibodies to IFNβ, the authors state that “IFNβ has little if any clinical and MRI efficacy in the presence of neutralising antibodies.” We think it is appropriate to be more circumspect, as most published studies suggest that in NAB positive patients, clinical (and MRI) efficacy of interferon treatment is present when compared to placebo, and that there is some evidence that more immunogenic higher dose treatment can …
- Subjects :
- Context (language use)
Placebo
Antiviral Agents
Antibodies
Multiple Sclerosis, Relapsing-Remitting
Neutralization Tests
Interferon β
Interferon
Correspondence
Humans
Medicine
Clinical significance
Treatment Failure
Antibody-Producing Cells
Immunoassay
Clinical Trials as Topic
Interferon beta
biology
business.industry
Multiple sclerosis
Interferon-beta
medicine.disease
Psychiatry and Mental health
Immunology
biology.protein
Surgery
Neurology (clinical)
Antibody
business
medicine.drug
Subjects
Details
- ISSN :
- 00223050
- Volume :
- 74
- Database :
- OpenAIRE
- Journal :
- Journal of Neurology, Neurosurgery & Psychiatry
- Accession number :
- edsair.doi.dedup.....9c82e1b26c44717e264350c059e086f2